Journal of Clinical Oncology, Vol 16, 2745-2751, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment

F Saliba, R Hagipantelli, JL Misset, G Bastian, G Vassal, M Bonnay, P Herait, C Cote, M Mahjoubi, D Mignard and E Cvitkovic
Paul Brousse Hospital, Villejuif, France.

PURPOSE: Irinotecan (CPT-11), a camptothecin derivative, has shown efficacy against colorectal cancer. Delayed-onset diarrhea is its main limiting toxicity. The aim of this study was to determine the pathophysiology of CPT-11-induced delayed-onset diarrhea and assess the efficacy of combined antidiarrheal medication in a phase II, prospective, successive-cohorts, open study. PATIENTS AND METHODS: Twenty-eight patients with advanced colorectal cancer refractory to fluorouracil (5-FU) therapy received CPT-11 350 mg/m2 every 3 weeks. The first cohort of 14 consecutive patients explored for the mechanism of diarrhea received acetorphan (a new enkephalinase inhibitor) 100 mg three times daily; the second 14-patient cohort received, in addition to acetorphan, loperamide 4 mg three times daily. Before treatment, and if late diarrhea occurred, patients underwent colon mucosal biopsies for CPT-11 and topoisomerase I levels; intestinal transit time; fecalogram; fat and protein excretion; alpha1-antitrypsin clearance; D- xylose test; blood levels for vasoactive intestinal polypeptide, glucagon, gastrin, somatostatin, prostaglandin E2, and carboxylesterase; CPT-11/SN-38 and SN-38 glucuronide pharmacokinetics; and stool cultures. RESULTS: Delayed-onset diarrhea occurred during the first three treatment cycles in 23 patients (82%). Electrolyte fecal measurements showed a negative or small osmotic gap in nine of nine patients and an increased alpha1-antitrypsin clearance in six of six patients. There were no modifications in stool cultures or hormonal dysfunction. Four of 11 patients (36%) with delayed-onset diarrhea in the first cohort responded to acetorphan, whereas nine of 10 patients (90%) responded to the combination of acetorphan and loperamide (P < .02). CONCLUSION: CPT-11-induced delayed-onset diarrhea is caused by a secretory mechanism with an exudative component. Early combined treatment with loperamide and acetorphan seems effective in controlling the diarrheal episodes.

This article has been cited by other articles:

				M. M. Javle, S. Cao, F. A. Durrani, L. Pendyala, D. D. Lawrence, P. F. Smith, P. J. Creaven, D. C. Noel, R. V. Iyer, and Y. M. Rustum Celecoxib and Mucosal Protection: Translation from an Animal Model to a Phase I Clinical Trial of Celecoxib, Irinotecan, and 5-Fluorouracil Clin. Cancer Res., February 1, 2007; 13(3): 965 - 971. [Abstract] [Full Text] [PDF]

				L. Tentori, C. Leonetti, M. Scarsella, A. Muzi, E. Mazzon, M. Vergati, O. Forini, R. Lapidus, W. Xu, A. S. Dorio, et al. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma FASEB J, August 1, 2006; 20(10): 1709 - 1711. [Abstract] [Full Text] [PDF]

				G. Brandi, J. Dabard, P. Raibaud, M. Di Battista, C. Bridonneau, A. M. Pisi, A. M. M. Labate, M. A. Pantaleo, A. De Vivo, and G. Biasco Intestinal Microflora and Digestive Toxicity of Irinotecan in Mice Clin. Cancer Res., February 15, 2006; 12(4): 1299 - 1307. [Abstract] [Full Text] [PDF]

				O. Soepenberg, H. Dumez, J. Verweij, F. A. de Jong, M. J.A. de Jonge, J. Thomas, F. A.L.M. Eskens, R. H.N. van Schaik, J. Selleslach, J. ter Steeg, et al. Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors Clin. Cancer Res., February 15, 2005; 11(4): 1504 - 1511. [Abstract] [Full Text] [PDF]

				M. Michael, M. Brittain, J. Nagai, R. Feld, D. Hedley, A. Oza, L. Siu, and M. J. Moore Phase II Study of Activated Charcoal to Prevent Irinotecan-Induced Diarrhea J. Clin. Oncol., November 1, 2004; 22(21): 4410 - 4417. [Abstract] [Full Text] [PDF]

				G. Vassal, F. Doz, D. Frappaz, K. Imadalou, E. Sicard, A. Santos, J. O'Quigley, C. Germa, M.-L. Risse, D. Mignard, et al. A Phase I Study of Irinotecan As a 3-Week Schedule in Children With Refractory or Recurrent Solid Tumors J. Clin. Oncol., October 15, 2003; 21(20): 3844 - 3852. [Abstract] [Full Text] [PDF]

				C.-J. Tai, J.-H. Liu, W.-S. Chen, J.-K. Lin, W.-S. Wang, C.-C. Yen, T.-J. Chiou, and P.-M. Chen Irinotecan (CPT11) Plus High-dose 5-Fluorouracil (5-FU) and Leucovorin (LV) as Salvage Therapy for Metastatic Colorectal Cancer (MCRC) after Failed Oxaliplatin Plus 5-FU and LV: a Pilot Study in Taiwan Jpn. J. Clin. Oncol., March 1, 2003; 33(3): 136 - 140. [Abstract] [Full Text] [PDF]

				R. Garcia-Carbonero and J. G. Supko Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins Clin. Cancer Res., March 1, 2002; 8(3): 641 - 661. [Abstract] [Full Text] [PDF]

				T. Ikegami, L. Ha, K. Arimori, P. Latham, K. Kobayashi, S. Ceryak, Y. Matsuzaki, and B. Bouscarel Intestinal Alkalization As a Possible Preventive Mechanism in Irinotecan (CPT-11)-induced Diarrhea Cancer Res., January 1, 2002; 62(1): 179 - 187. [Abstract] [Full Text] [PDF]

				M. L. Rothenberg Irinotecan (CPT-11): Recent Developments and Future Directions-Colorectal Cancer and Beyond Oncologist, February 1, 2001; 6(1): 66 - 80. [Abstract] [Full Text]

				T. Suzuki, H. Sakai, A. Ikari, and N. Takeguchi Inhibition of Thromboxane A2-Induced Cl- Secretion by Antidiarrhea Drug Loperamide in Isolated Rat Colon J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 233 - 238. [Abstract] [Full Text]

				R. Khanna, C. L. Morton, M. K. Danks, and P. M. Potter Proficient Metabolism of Irinotecan by a Human Intestinal Carboxylesterase Cancer Res., September 1, 2000; 60(17): 4725 - 4728. [Abstract] [Full Text]

				R.B. Arbuckle, S.L. Huber, and C. Zacker The Consequences of Diarrhea Occurring During Chemotherapy for Colorectal Cancer: A Retrospective Study Oncologist, June 1, 2000; 5(3): 250 - 259. [Abstract] [Full Text]

				M. K. Ma, W. C. Zamboni, K. M. Radomski, W. L. Furman, V. M. Santana, P. J. Houghton, S. K. Hanna, A. K. Smith, and C. F. Stewart Pharmacokinetics of Irinotecan and Its Metabolites SN-38 and APC in Children with Recurrent Solid Tumors after Protracted Low-Dose Irinotecan Clin. Cancer Res., March 1, 2000; 6(3): 813 - 819. [Abstract] [Full Text]

				D. Savarese, A. Al-Zoubi, and J. Boucher Glutamine for Irinotecan Diarrhea J. Clin. Oncol., January 14, 2000; 18(2): 450 - 450. [Full Text]

				E. Wasserman, C. Cuvier, F. Lokiec, F. Goldwasser, S. Kalla, D. Mery-Mignard, M. Ouldkaci, A. Besmaine, G. Dupont-Andre, M. Mahjoubi, et al. Combination of Oxaliplatin Plus Irinotecan in Patients With Gastrointestinal Tumors: Results of Two Independent Phase I Studies With Pharmacokinetics J. Clin. Oncol., June 1, 1999; 17(6): 1751 - 1751. [Abstract] [Full Text] [PDF]